The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 12, 2024

Filed:

Dec. 15, 2020
Applicant:

The Trustees of the University of Pennsylvania, Philadelphia, PA (US);

Inventors:

Evgeniy Eruslanov, Havertown, PA (US);

Steven Albelda, Philadelphia, PA (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/15 (2015.01); A61K 31/454 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C12N 5/0787 (2010.01);
U.S. Cl.
CPC ...
A61K 35/15 (2013.01); A61K 31/454 (2013.01); A61K 38/193 (2013.01); A61K 38/217 (2013.01); A61K 39/0011 (2013.01); A61K 39/39541 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12N 5/0642 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); A61K 2300/00 (2013.01); C12N 2501/22 (2013.01); C12N 2501/24 (2013.01); C12N 2501/599 (2013.01); C12N 2502/30 (2013.01);
Abstract

The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.


Find Patent Forward Citations

Loading…